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O
ver the course of the last half-century, we have
gleaned much about the developmental biology
of the pancreas and in particular the insulin-
producing b-cell, the autoimmune destruction
of which results in type 1 diabetes. Deciphering the mech-
anisms driving b-cell neogenesis in vivo holds great allure,
in large part because of the potential therapeutic applica-
tions that stand to be gained.
The ﬁeld of pancreas development was arguably estab-
lished by such scientists as Rutter, Grobstein, Wessells,
and Cohen in the 1960s. Their seminal studies were the
ﬁrst to demonstrate the signiﬁcance of the mesenchyme in
supporting development of the pancreas or indeed any
organ. Their work was further extended by Teitelman and
colleagues who did much to characterize pancreatic dif-
ferentiation via immunohistochemistry. Over the last two
decades, the emergence of increasingly elaborate knock-
out and transgenic mouse technologies has exponentially
expanded our insight into the signaling pathways and
transcriptional nexus governing pancreas development.
Thus, it is ﬁtting that this review will mainly focus on the
development of the pancreas and b-cells in the mouse.
Through recapitulating endogenous signaling pathways
governing b-cell neogenesis in the embryo, it has recently
proven possible to generate insulin-producing cells in vitro
from human embryonic stem cells (hESCs) (1). Although
this milestone accentuates the great therapeutic potential
of studying b-cell neogenesis in vivo, the currently insuf-
ﬁcient functionality of hESC-derived insulin cells argues the
case for further examination of b-cell development in order
to understand how and why such engineered cells differ
from their endogenous counterparts. It is likely that re-
solving these differences will lie in better characterizing the
relationships between the many signaling pathways and key
factors already known to govern the pancreatic program in
regards to spatial and temporal pancreatic expression and
their impact on pancreatic differentiation. It is envisaged
that such incremental knowledge gains will be applied to
the optimization of current stepwise hESC differentiation
protocols to generate transplantable insulin cells more remi-
niscent of endogenous b-cells. Although the direction of
the ﬁeld in broad terms is described above, in the follow-
ing review, which will focus on b-cell development from
pancreatic speciﬁcation onward, attention will be drawn to
more speciﬁc, outstanding questions in the current ﬁeld as
they arise.
SPECIFYING THE PANCREAS
Pancreas development in the mouse is ﬁrst morphologi-
cally discernable at embryonic day (e)8.75–9.0 with the
outgrowth of dorsal and ventral pancreatic “buds” (Fig. 1A-
D) on opposing sides of the foregut endoderm, marked by
expression of the transcription factor Pdx1 (refer to Table
1 for an overview of transcription factors regulating pan-
creas morphogenesis and b-cell neogenesis and summa-
rized phenotypes of mouse mutants). Pictet et al. (2) were
the ﬁrst, however, to propose that such budding is pre-
ceded by the acquisition of a so-called pancreatic state by
prepancreatic endoderm cells, a process they coined the
primary transition. Subsequent work has shown this en-
dodermal state to be conferred by a combination of cell
intrinsic regulators whose expression in the gut endoderm
is governed by extrinsic, mesodermally derived signals.
These include members of the hedgehog, transforming
growth factor (TGF)-b, ﬁbroblast growth factor (FGF),
bone morphogenetic protein (BMP), and retinoic acid (RA)
families of secreted factors. Much remains unknown about
how these pathways communicate with one another to
specify pancreatic endoderm, and it is likely that future
work will do much to dissect the interactions between
them.
MESODERMAL CUES
FGF, BMP, and hedgehog signaling. While expressed
throughout early foregut endoderm, Sonic hedgehog (Shh)
and Indian hedgehog (Ihh) are speciﬁcally excluded from
the prepancreatic domain, a phenomenon crucial for
pancreas speciﬁcation because hedgehog signaling has
been shown to inhibit both pancreas formation and Pdx1
expression ([3] and references therein). Experiments in
the chick have suggested that notochord-derived signals,
such as the TGF-b superfamily member activin-bB and
FGF2 repress Shh in the adjacent dorsal prepancreatic
endoderm (4–6). However, hedgehog exclusion from the
ventral prepancreatic endoderm is achieved via a distinct
notochord-independent mechanism. Intricate work by
Zaret and colleagues ([7] and references therein) pre-
dominantly using embryo culture models has shown that
this ventral foregut endoderm is bipotential, giving rise to
both liver and ventral pancreas with the latter being
formed by default. FGF signaling from the adjacent cardiac
mesoderm instead diverts ventral endoderm toward a liver
fate by inducing local Shh expression while the ventral
pancreatic program is initiated by those cells not exposed
to cardiac FGF. Concordantly, BMP signaling from the
septum transversum mesoderm similarly induces hepatic
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PERSPECTIVES IN DIABETESfate in ventral endoderm cells and, reciprocally, sup-
presses adoption of pancreatic fate ([7] and references
therein). Recent studies by the Zaret laboratory using
a novel half-embryo culture system have however revealed
that just a few hours later in development, BMP signaling
contrarily promotes pancreatic fate in ventral endoderm
(7), exemplifying how dynamically cells change their
competence to respond to the inductive effects of pro-
gramming signals in development. Although these ﬁndings
illustrate the great utility of half-embryo and organ culture
models, the experimental system is not without caveats.
These include developmental delay in comparison with in
situ organs, high explant-to-explant variability, incomplete
tissue exposure to exogenously applied agonists, and
failure to fully recapitulate in vivo developmental pro-
cesses. Thus, explant studies are of most beneﬁt when
complementing in vivo genetic analyses. It currently
remains unknown whether the indicated liver-pancreas
bipotentiality of foregut endoderm truly exists at the level
of a single endoderm cell, or whether the foregut endo-
derm population is heterogeneous in terms of organ line-
age commitment.
Retinoic acid signaling. RA, synthesized by the enzyme
encoded by Raldh2 (or Aldh1a2), regulates global ante-
roposterior patterning of gut endoderm far upstream of
Pdx1. While zebraﬁsh embryos lacking RA fail to correctly
specify both pancreas and liver because of endoderm
anteriorization (8), in Xenopus and mouse, only dorsal
pancreas speciﬁcation is RA-dependent (9–11). Although
some evidence in Xenopus suggests that RA may promote
pancreas formation by downregulating Shh (9), RA in-
duction of the dorsal pancreatic program is probably
hedgehog-independent in mammals (10).
Endothelial signals. Tissue recombination experiments
and studies of endothelium-deﬁcient Kdr1
2/2 (Flk1) mice
have revealed that endothelium of the fusing dorsal aortae
is required for emergence of the adjacent dorsal pancreatic
endoderm and its maintenance of Pdx1 expression as well
as induction of a second crucial pancreatic transcription
factor, Ptf1a (12,13). The dorsal aorta endothelium has
more recently been shown to also play a role in promoting
the survival of dorsal pancreatic mesenchyme (14). In
contrast, ventral pancreas emergence and Ptf1a expres-
sion occur independently of the underlying vitelline vein
endothelium (13), consistent with the existence of distinct
programs for specifying dorsal versus ventral pancreas.
PANCREAS POSITIONING
Establishing the proper anteroposterior location of the
prepancreatic domain within the gut endoderm requires its
interaction with the mesoderm. The transcription factors
Cdx4, Bapx1 (Nkx3.2), and Hhex all serve to correctly
position the emerging pancreatic buds within the gut en-
doderm. The posteriorly shifted pancreas, liver, and small
intestine in Cdx4-deﬁcient zebraﬁsh show that endo-
dermally expressed Cdx4 confers posterior identity to gut
endoderm and may suppress adoption of pancreatic fate
by preventing RA signal transduction in posterior endo-
derm (15). Both Bapx1 and Hhex regulate the adoption of
pancreatic fate by controlling morphogenetic movements,
thereby governing proximity of prepancreatic endoderm to
signaling centers. Bapx1 acts in the splenic mesenchyme
to correctly position and partition the developing dorsal
pancreas and spleen (16). Hhex instead directs speciﬁca-
tion of the ventral pancreas by regulating proliferation and,
therefore, positioning of the leading edge of ventral de-
ﬁnitive endoderm cells that extend beyond the cardiac
mesoderm during closure of the gut tube (17) (see “FGF,
BMP, and hedgehog signaling” above). In Hhex
2/2 mice,
FIG. 1. Gross morphology of the developing pancreas. Sox9-eGFP demarcates the dorsal pancreatic endoderm (dp) at e9.5 (A) and both dorsal (dp)
and ventral (vp) pancreatic buds at e10.5 (B) (embryos shown at same scale). Staining for Pdx1 highlights the epithelium of the pancreatic buds,
antral stomach (as), common bile duct (cbd), and duodenum (duo) at e10.5 (C) and e11.5 (D); early glucagon
1 endocrine cells differentiate at the
periphery of the dorsal pancreatic bud and, following a temporal delay, in the ventral pancreatic bud (z-stack projections shown at same scale).
X-Gal staining for lacZ expressed from the Pdx1 locus highlights the dorsal bud-derived (dp) and ventral bud-derived (vp) pancreas, antral
stomach (as), common bile duct (cbd), extrahepatic bile ducts (ehd), and duodenum (duo) at e12.5 (E) and e15.5 (F). Gross morphology of the
perinatal (e18.5) (G) and adult (four-month-old) (H) pancreas: stom, stomach; spl, spleen. F–H: Pancreas tissue is demarcated by red dashed lines.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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become positioned beyond the liver-inducing inﬂuence of
the cardiac mesoderm and, consequently, ventral pancreas
is not speciﬁed (17).
INTRINSIC FACTORS
Assigning pancreatic fate: deciphering the pancreatic
code. Pdx1 has long been regarded as the marker for
identifying presumptive pancreatic progenitors because it
demarcates the prepancreatic endoderm from e8.5, prior
to pancreatic bud emergence. Subsequently, however, Pdx1
additionally marks the presumptive extrahepatobiliary sys-
tem, antral (posterior) stomach, and duodenum (18–20)
(Fig. 1C-F). In contrast, expression of Ptf1a in the gut en-
doderm is exclusively pancreas-speciﬁc (21,22). Inter-
estingly, despite their early expression in prepancreatic
endoderm, neither Pdx1 nor Ptf1a is required for dorsal
pancreatic speciﬁcation: mouse embryos lacking either
gene do form a dorsal pancreatic rudiment though it sub-
sequently growth-arrests at around e10.5 (19–21,23).
Lineage-tracing experiments have revealed that in the ab-
sence of Ptf1a, endodermal cells fated to form ventral
pancreas switch fate and become incorporated into duo-
denal and common bile duct (CBD) endoderm (21,24).
These studies prompted speculation that Ptf1a expression
within the broader Pdx1
1 domain deﬁnes a so-called
pancreas code instructing adoption of pancreatic identity.
However, contrary to this idea, concerted loss of both
Pdx1 and Ptf1a is insufﬁcient to prevent initiation of a
pancreatic program in either Xenopus (25) or mouse (24),
strongly pointing to the existence of parallel genetic pro-
grams driving speciﬁcation of dorsal pancreas. Most re-
cently, a role has been demonstrated for the transcription
factor Sox17 in assigning ventral pancreatic versus extra-
hepatobiliary fate in ventral foregut progenitor cells (26).
In the absence of Sox17, ventral pancreatic fate is pro-
moted at the expense of extrahepatobiliary fate while the
reverse results from Sox17 misexpression in presumptive
pancreatic progenitor cells (26). In contrast to Ptf1a and
Sox17, which are functionally required for proper ventral
pancreas development, the transcription factor Hb9
(encoded by Hlxb9) plays a crucial role in early morpho-
genesis of the dorsal pancreas. Hlxb9
2/2 mice display
complete dorsal pancreas agenesis, while the early ventral
pancreatic program is unperturbed (27,28).
On account of the key roles played by Pdx1 and Ptf1a in
early pancreas development, one intense focus of interest is
the search for transcription factors regulating their expres-
sion (reviewed in [29]). Both Foxa2 (formerly Hnf3b)a n d
Hnf6 (Onecut1) have been identiﬁed as potential activators
of Pdx1 expression (30,31) but, in apparent contradiction to
this function, are both dispensable for Pdx1 activation and
early pancreas morphogenesis (31–33). Similarly, some ev-
idence points to the transcription factor Hnf1b (Tcf2,
vHnf1) regulating Ptf1a (34). Phenocopying the Ptf1am u -
tant, in Hnf1b-nullizygous mice, the ventral pancreas is
absent while the dorsal bud, which fails to express Ptf1a,
growth-arrests (34). Lineage-tracing will be required to de-
ﬁnitively test whether Hnf1b-deﬁcient presumptive ventral
pancreatic endoderm cells contribute to adjacent endo-
dermally derived organs as in Ptf1a
2/2 mice. Based on the
discordance between dorsal and ventral pancreatic pheno-
types in mice deﬁcient for the endodermally expressed
factors Ptf1a, Hnf1b, Pdx1, or, most notably, Hlxb9,i th a s
been suggested that dorsal and ventral anlagen are speciﬁed
by distinct cell-intrinsic programs (35). In those mutants in
which ventral pancreas morphogenesis is more severely
perturbed than dorsal, it should, however, be considered
that the divergent phenotypes could also be explained by
differences in the morphogenetic events leading to the
emergence of the two rudiments. While the larger dorsal
bud arises in relative isolation, the contiguity of the emerg-
ing, smaller ventral pancreas and CBD (Figs. 1C-D and 2)
render the two nearly undistinguishable in the event of
ventral pancreatic hypoplasia. As such, early growth-arrest
of an initially speciﬁed ventral pancreatic bud can result in
its assimilation into the adjacent endoderm of the CBD and
duodenum, manifesting in apparent ventral pancreas agen-
esis. For this reason, the molecular programs governing
dorsal versus ventral pancreas speciﬁcation are most likely
more similar than currently perceived.
GROWTH OF THE PANCREAS: PROGENITOR CELL
PROLIFERATION AND ORGAN MORPHOGENESIS
Following speciﬁcation, the dorsal pancreatic bud arises
just posterior to the presumptive stomach, while the ventral
pancreas emerges opposite, ventrally adjacent to the he-
patic endoderm (Figs. 1A–D and 2). Between e10.5 and
e12.5, the two pancreatic buds grow alongside the pre-
sumptive duodenum and stomach. Rotation of the gut tube
leads to their fusion on the dorsal side of the gut by e12.5
(Fig. 1E), forming a single organ while, simultaneously,
multiple rounds of branching morphogenesis take place,
initiating at e11.5 (Fig. 2). Branching morphogenesis in-
volves the restructuring of the pancreatic epithelium into
a complex and highly organized tubular network. Recent
intricate studies by Semb and colleagues (36) have revealed
that tube formation occurs in a multistep process: 1)s c a t -
tered microlumens arise stochastically within the pancre-
atic epithelium at e11.5; 2) microlumens expand through
their induction of apical cell polarity in neighboring cells;
3) lumens coalesce with one another at e12.5 into a con-
tinuous luminal network; which 4) remodels between e13.5
and e15.5 into a tubular network (Fig. 2). Using Pdx1-Cre-
driven ablation in the early pancreas, Kesavan et al. (36)
demonstrated that the r-GTPase Cdc42 plays a crucial role
in tubulogenesis by concordantly establishing multicellular
microlumens and apical epithelial polarity. Further ex-
tending this ﬁnding, the inducible ablation of Cdc42 in fully
polarized tubular epithelial cells results in their loss of apical
cell polarity, uncovering an additional cell-autonomous role
for Cdc42 in the maintenance of apical polarization (36).
PROPERTIES OF EARLY PANCREATIC EPITHELIAL CELLS
Although a few glucagon
1 endocrine cells differentiate (Fig.
1C-D) immediately following bud outgrowth (e9.5–e11.5),
the majority of pancreatic cells are still undifferentiated and
continue to coexpress Pdx1 (Fig. 1C-D) and Ptf1a. Lineage-
tracing has shown such cells to give rise to all mature
pancreatic cell types: the exocrine acinar and ductal cells
and the ﬁve endocrine cell types (21,37). Based on these
properties, Pdx1
1 and Ptf1a
1 cells of the early pancreatic
epithelium have been referred to as multipotent pancreatic
progenitors (MPCs) (Fig. 2). However, because in vivo
lineage-tracing studies assessed the developmental poten-
tial of the entire population, it is still unclear whether
progenitors of the early pancreas are a heterogeneous
population with some or all being precommitted to a par-
ticular cell fate as they arise. Consistent with this model,
single-cell transcript analysis has revealed the existence
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Overview of transcription factors governing pancreas development and b-cell neogenesis and phenotypes of respective mouse
mutants
Factor Type Onset* Expression/role(s)
Pancreatic phenotype of mouse
mutant(s)
Bapx1 aka Nkx3.2 HD #e9.5 Acts in splenic mesenchyme to
correctly position and partition
developing d.p. and spleen (16)
Bapx1
2/2: d.p. undergoes
metaplastic transformation into
intestinal-like tissue because of
prolonged interaction with splenic
mesenchyme (16)
Hhex HD e7.0 Directs v.p. speciﬁcation (17) Hex
2/2: v.p. not speciﬁed: reduced
proliferation of bipotential ventral
foregut endoderm cells does not
position them beyond prohepatic
inﬂuence of the cardiac mesoderm
to permit pancreatic induction
(17)
Sox17 HMG box #e5.5 Expressed throughout endoderm
postgastrulation (113); assigns
ventral pancreatic vs.
extrahepatobiliary fate in ventral
foregut progenitor cells (26)
Foxa3-Cre; Sox17
ﬂ/ﬂ: loss of biliary
primordium (gall bladder and
cystic duct); ectopic pancreas in
common duct (26). Pdx1
tTa/1;
tetO-Sox17: d.p. and v.p.
agenesis (26)
Foxa2 aka Hnf3b winged helix #e5.5 Expressed throughout the early
pancreatic endoderm; restricted to
acinar and endocrine cells by late
gestation (30;114–115); required
for islet function (32;118)
Foxa2
2/2: embryonic lethal; absence
of foregut endoderm (116;117)
Foxa3-Cre; Foxa2
ﬂ/ﬂ:
hypoglycemia; hypoglucagonemia;
loss of a-cells (32). Ins-Cre;
Foxa2
ﬂ/ﬂ: hyperinsulinemic
hypoglycemia (118)
Hnf6 aka OC1 HD #e9.0 Expressed in MPCs and becomes
restricted to acini and ducts
(31;119;120); required for
endocrine differentiation (33)
Hnf6
2/2: d.p. and v.p. hypoplastic
(persists postnatally) because of
delayed Pdx1 expression; loss of
Ngn3
1 endocrine progenitors;
reduced endocrine cell numbers
(31;33)
Hb9 (from Hlxb9 gene) HD #e8.0 Foregut and midgut endoderm, then
dorsal and ventral pancreatic
buds; becomes b-cell–restricted
(27;28). Required for dorsal
pancreas development and b-cell
terminal differentiation (27;28)
Hlxb9
2/2: d.p. agenesis (27;28);
reduced numbers of b-cells in
ventral pancreas, which also
showed decreased Glut2 (27;28)
and Nkx6.1 expression (27);
increased numbers of d-cells (28)
Hnf1b aka Tcf2 aka
vHnf1
HD #e8.5 Expressed in MPCs and progenitor
cords (34;121); required for
growth of pancreatic buds (34)
Tcf2
2/2: v.p. undetectable; d.p.
growth-arrested $e10.5 and lost
by e13.5 because of reduced
proliferation (34)
Isl1 HD #e9.0 Expressed in dorsal pancreatic
mesenchyme and in endocrine
cells (42). Required for pancreatic
epithelial growth and endocrine
differentiation (42). Required for
the maturation, proliferation and
survival of second wave endocrine
cells (110)
Isl1
2/2: absence of dorsal pancreatic
mesenchyme and so defective
exocrine differentiation; complete
abrogation of endocrine
development because of function
in epithelial cells (42)
Pdx1-Cre
late; Isl1
ﬂ/ﬂ:
hyperglycemia; islet hypoplasia;
reduced numbers of Pax6
1 late
endocrine progenitors; decreased
proliferation and increased
apoptosis of endocrine cells;
impaired endocrine cell
maturation (110)
Pdx1 HD e8.5–e8.75 Expressed in MPCs (37), progenitor
cords then b-cells (18–20);
required for growth of pancreatic
buds (19;20;24)
Pdx1
2/2: v.p. agenesis; d.p.
growth-arrested $e10.5 (19;20;24)
Pdx1
1/2: glucose intolerance;
impaired GSIS; increased
susceptibility to b-cell apoptosis
(122)
Continued on next page
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Continued
Factor Type Onset* Expression/role(s)
Pancreatic phenotype of mouse
mutant(s)
Ptf1a bHLH e8.5–e8.75 Expressed in MPCs (21), then acinar
cells (22); promotes ventral
pancreatic fate (21); governs
acinar program (21;23;62)
Ptf1a
2/2: v.p. agenesis (cells
diverted to intestinal and CBD
fate); d.p. growth-arrested $e10.5;
in d.p., endocrine cells present but
acinar cells lost (21;23;24)
Hes1 bHLH Maintains MPCs by preventing cell
cycle exit and differentiation
(49–51) by repressing Ngn3 (53)
and p57 (49), respectively
Hes1
2/2: d.p. and v.p. hypoplasia
because of MPC pool depletion
through precocious differentiation
(49–51); acinar dysgenesis (50);
ectopic pancreas in distal
stomach, duodenum, and CBD
(123)
Sox9 HMG box #e9.0 Expressed in MPCs and progenitor
cords (55;63;124); required for
growth of pancreatic buds (55)
and generation of Ngn3
1
endocrine progenitors (63)
Pdx1-Cre
early; Sox9
ﬂ/ﬂ: d.p. and v.p.
hypoplasia because of MPC pool
depletion; increased apoptosis,
reduced proliferation, and
precocious differentiation (55)
Pdx1-Cre
early; Sox9
ﬂ/1: islet
hypoplasia because of reduced
numbers of Ngn3
1 endocrine
progenitor cells (63)
Nkx6.1 HD #e9.0 Expressed in MPCs, Ngn3
1
endocrine progenitors, then
b-cells (62;93). Speciﬁes MPCs
toward an endocrine/ductal fate
(62). Required for b-cell
differentiation (93)
Nkx6.1
2/2: 85% reduction in b-cell
numbers (93); additional loss of
a-cells in Nkx6.1
2/2; Nkx6.2
2/2
mutants (125). Nkx6.1
2/2: ectopic
trunk Ptf1a expression and loss
of Ngn3
1 cells; both more acute in
Nkx6.1
2/2; Nkx6.2
2/2 mice (62)
Nkx6.2 HD #e10.5 Expressed in MPCs, then by e15.5,
only in some glucagon
1 cells and
acinar cells (125). Functionally
equivalent to Nkx6.1 (126)
Nkx6.2
2/2: no obvious pancreatic
phenotype (125)
Ngn3 bHLH #e9.5 Endocrine progenitor cell marker
then later expressed in islet cells
(51;74;75); cell-autonomously
induces commitment to endocrine
lineage (51); required for
formation of all endocrine cells
(74). Maintains endocrine function
(75)
Ngn3
2/2: absence of all pancreatic
endocrine and intestinal
enteroendocrine cells (74;78;79);
acinar dysmorphogenesis (74)
Ins2-Cre; Ngn3
fl/-: hyperglycemia;
impaired b-cell maturation (75)
Ia1 aka Insm1 Zinc ﬁnger #e9.5 Expressed in endocrine progenitors
and some differentiated endocrine
cells in Ngn3-dependent manner
(83;84)
Ia1
2/2: impaired differentiation of
pancreatic a- and b-cells and gut
enteroendocrine cells (84)
Neuro D1 aka Beta2 bHLH #e9.5 Expressed in differentiating and
mature endocrine cells (83;86).
Required for normal islet
formation (86) and for the
acquisition and maintenance of
the fully functional, glucose-
responsive b-cell phenotype (111)
NeuroD1
2/2: islet hypoplasia and
dysgenesis, endocrine apoptosis
and aberrant differentiation;
disrupted enteroendocrine
differentiation (86). RIP-Cre
(or Pdx1-Cre
ERT); NeuroD1
ﬂ/-:
hyperglycemia; reduced
pancreatic insulin (ins1 mRNA
reduced); b-cell immaturity (111)
Nkx2.2 HD #e9.5 Expressed in MPCs, then a-, b-, and
PP-cells (87). Required for b- and
a-cell development (87;89)
Nkx2.2
2/2: b-cell loss and a- and
PP-cell reduction; e-cell numbers
expanded (87;89)
Pax4 HD #e9.5 Expressed in endocrine progenitors
then becomes restricted to b- and
d-cells (88); Ngn3-dependent
expression. Promotes allocation
to b-cell fate (88–90)
Pax4
2/2: b- and d-cell loss; e- and
a-cell numbers expanded (88–90)
Continued on facing page
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pression proﬁle (38). Whether a single cell in the early
embryonic pancreas is truly multipotent has yet to be
demonstrated: only through single-cell colony-forming
assays can unequivocal proof of multipotency be acquired.
Maintenance of early progenitor pool size is critical for
normal pancreas morphogenesis. A recent study (39) using
temporally controlled ablation has shown that while pro-
genitor depletion prior to e9.5 has negligible impact on
ﬁnal pancreas size, their diminution up until e11.5 causes
pancreatic hypoplasia which persists into adulthood. Thus,
the bulk of the progenitor pool is generated between e8.5
and e12.5 and if a proportion is lost, compensatory growth
is unable to occur. As such, the size of the initial pro-
genitor pool predetermines ﬁnal pancreas size.
ROLE OF MESENCHYMAL SIGNALS
The seminal tissue recombination experiments of Golosow,
Grobstein, Wessells, and Cohen in the 1960s revealed
FIG. 2. Overview of major events in pancreatic morphogenesis. By e10.5, the anlagen of the dorsal (dp) and ventral (vp) pancreas, liver, stomach
(stom), and duodenum are established; rapid growth of the pancreatic buds occurs through expansion of the MPC population. From around e11.0
on, neighboring cells undergo cell polarization, generating microlumens with a common apical surface. Over the next few days, microlumen ex-
pansion and fusion forms a ductal luminal network; branching morphogenesis of the pancreatic epithelium occurs concordantly with segregation of
MPCs by e12.5 into an acinar-committed Ptf1a
1 “tip” domain and an Nkx6
1 central “trunk” ﬁeld fated to give rise to the ductal network and
endocrine cells. By e15.5, the midpoint of the secondary transition, much acinar cell neogenesis has occurred and the acinar compartment expands
predominantly through mitosis. Ngn3
1 endocrine progenitor cells delaminate from the Sox9
1 Hnf1b
1 Muc1
1 ductal epithelium and give rise to
endocrine cells, which coalesce to form nascent islets.
TABLE 1
Continued
Factor Type Onset* Expression/role(s)
Pancreatic phenotype of mouse
mutant(s)
Arx HD #e9.5 Expressed in a- and PP-cells in
Ngn3-dependent manner (94;95);
promotes acquisition of a- and
PP-cell fate; represses b- and
d-cell fate (94)
Arx
2/2: a-cell loss; b- and d-cell
numbers expanded (94)
Rfx6 Winged helix #e9.0 Expressed in endocrine progenitors
and all islet cell types in
Ngn3-dependent manner (97;98).
Restricts expression of Nkx6.1
(97)
Rfx6
2/2: small bowel obstruction;
incompletely penetrant pancreatic
hypoplasia; loss of all hormone-
expressing (except PP-) cells;
partial activation of endocrine
program (97)
MafA Basic leucine
zipper
#e13.5 b-Cell–speciﬁc activator of insulin
gene transcription (104 [review]);
exclusive expression in insulin
1
cells from e13.5 onwards (105;107)
MafA
2/2: no obvious pancreatic
developmental phenotype;
development of glucose
intolerance postnatally (108)
MafB Basic leucine
zipper
#e10.5 Expressed in insulin
1 and
glucagon
1 cells by e12.5;
restricted to a-cells postnatally
(106;107). Regulates transcription
of key factors required for a- and
b-cell maturation (109)
MafB
2/2: a- and b-cell numbers
reduced throughout pancreas
development while total
endocrine cell numbers
unaffected; insulin
1 cell
neogenesis delayed (109)
*Onset of expression in or adjacent to the prepancreatic or pancreatic domain. aka, also known as; d.p., dorsal pancreas; GSIS, glucose-
stimulated insulin secretion; v.p., ventral pancreas.
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crucially dependent upon diffusible, permissive signals from
the adjacent pancreatic mesenchyme (40,41). It is only rel-
atively recently, through the use of transgenic and gene
knockout mice that we have begun to characterize these
mesenchymal cues that comprise not only diffusible sig-
naling molecules but transcription factors also.
Isl1. RA promotes the expression of the transcription fac-
tor Isl1 in the dorsal pancreatic mesenchyme (10). Without
Isl1, the dorsal pancreatic mesenchyme is almost entirely
absent at e9.5, and the dorsal pancreas growth-arrests, re-
vealing a crucial role for Isl1 in promoting pancreatic
growth and differentiation through a requirement in the
maintenance of the dorsal pancreatic mesenchyme (42).
FGF signaling. Of the broad spectrum of FGF ligands and
their receptors expressed in the developing rodent pancreas,
the role of the FGF10-FGFR2IIIb axis is arguably the best
characterized. FGF10 is expressed in dorsal and ventral
pancreatic mesenchyme from e9.5–e11.5, coincident with
both pancreatic epithelial expression of it’sr e c e p t o r
FGFR2IIIb and rapid pancreatic epithelial growth (43).
Without either FGF10 or FGFR2b, dorsal and ventral pan-
creatic hypoplasia occurs because of reduced proliferation of
the early progenitor pool, showing mesenchymal FGF10 sig-
naling to be required for MPC maintenance (43,44). Rein-
forcing this conclusion, studies by Norgaard et al. (45) have
demonstrated that ectopic Pdx1 promoter-driven expression
of FGF10 in pancreatic epithelium both maintains cells in an
undifferentiated state and promotes their proliferation.
BMP and Wnt signaling. Although studied in substantially
less depth than the FGF signaling pathway, recent studies
have suggested that Wnt and BMP signaling in the mesen-
chyme also provide important cues for expansion of the
early pancreatic epithelium (46,47). The PHD-ﬁnger protein
pygopus was initially identiﬁed in Drosophila as a nuclear
coactivator of Wg (ﬂy homolog of mammalian Wnt) sig-
naling (reviewed in [48]). Deﬁciency for the pygopus ho-
molog mPygo2 in mice results in pancreas hypoplasia
because of decreased progenitor cell proliferation after
e12.5 when canonical Wnt signaling is both active in the
pancreatic mesenchyme and mPygo2-dependent (46). The
absence of pancreatic hypoplasia after conditional ablation
of mPygo2 in the pancreatic epithelium suggests that de-
creased mesenchymal Wnt signaling accounts for the ob-
served pancreas hypoplasia in mPygo2 null mutant mice
(46). While Wnt signaling activity is also detected in pan-
creatic epithelial cells (46), BMP signaling as revealed by
phospho-Smad1,5,8 immunoreactivity is restricted to the
early pancreatic mesenchyme in both mouse and chick
(47). The observation that abrogation of BMP signaling with
the BMP antagonist Noggin results in pancreatic hypoplasia
and diminished epithelial branching (47) suggests a role for
mesenchymal BMP signaling in promoting growth of the
early pancreatic epithelium. One hindrance in genetically
dissecting the roles of Wnt and BMP signaling in pancreatic
morphogenesis is redundancy between the large number of
ligands and receptors that can mask important gene func-
tions in loss-of-function models.
EPITHELIAL CELL INTRINSIC CUES
In addition to extrinsic signals from the mesenchyme,
pancreatic growth is also governed by signaling pathways
and transcription factors that operate within the epithelium.
While a few studies have begun to address the relationship
between signaling events and transcriptional responses
in progenitors, the mechanisms through which speciﬁc
signaling pathways affect gene transcription remain largely
unexplored.
The Notch pathway. While the aforementioned study by
Norgaard et al. (45) has hinted that the effects of mesen-
chymal FGF10 signaling are transduced through Notch path-
way activation in the pancreatic epithelium, overwhelming
evidence supports the involvement of Notch in the mainte-
nance of undifferentiated progenitors. Inactivation of the
Notch pathway constituents Hes1 (the Notch downstream
effector in the pancreas), RBP-Jk,o rD-like 1 (Dll1)i nm i c e
leads to cell cycle arrest, precocious endocrine differentia-
tion, and MPC pool depletion, resulting in pancreatic hypo-
plasia (49–52). As well as repressing the cyclin-dependent
kinase inhibitor p57 in MPCs (49), Hes1 also represses the
pancreatic proendocrine transcription factor Ngn3 (53).
Furthermore, Hes1 and the related protein Hey1 inhibit Ptf1a
(54), which in addition to being required for pancreas spec-
iﬁcation, subsequently promotes acquisition of acinar fate
(21,23). Thus, Notch signaling within the pancreatic epithe-
lium maintains progenitors in an undifferentiated state.
Sox9. Similar to Pdx1 and Ptf1a (19–21,23), the transcription
factor Sox9 is crucial for proper expansion of the MPC pool
to generate a normal pancreas. Conditional ablation of Sox9
in MPCs results in almost complete pancreas agenesis be-
cause of MPC pool depletion through reduced proliferation,
apoptosis, and premature differentiation (55). Loss of Hes1
in Sox9-deﬁcient MPCs indicates that Sox9-mediated pro-
genitor cell maintenance may be at least partially Notch-
dependent (55). Future work will ascertain at what level of
the Notch pathway interaction with Sox9 occurs.
The Wnt pathway. Attenuation of the b-catenin–
dependent canonical Wnt pathway in MPCs has been
shown by some (though not by all) groups to result in de-
creased progenitor proliferation, manifesting in pancreatic
hypoplasia at birth (56,57). Intriguingly, hyperactivation of
canonical Wnt signaling in MPCs also produces hypoplasia,
due apparently to loss of mesenchymal FGF10 signaling,
concomitant with increased hedgehog signaling (58,59).
However, analysis of temporally inducible Wnt ablation and
hyperactivation mouse models will be needed to determine
whether the observed pancreatic hypoplasia truly reﬂects
a role for Wnt signaling in pancreatic progenitor cell ex-
pansion or whether it instead results from earlier endo-
dermal patterning defects.
ESTABLISHING ENDOCRINE- AND EXOCRINE-
COMMITTED COMPARTMENTS
Between e12 and e14 (the branching phase of pancreas
development), the apparently homogeneous ﬁeld of MPCs in
the early pancreatic buds resolves into an acinar-committed
distal “tip” domain (marked by Cpa, c-Myc,a n dPtf1a) (60)
and an endocrine- or ductal-committed central core or
“trunk” region (61) (Fig. 2). Only recently has insight been
gained into the molecular mechanism governing this early
lineage allocation. Through genetic loss- and gain-of-
function studies, our laboratory showed that Nkx6 (Nkx6.1
and Nkx6.2) and Ptf1a transcription factors are required
and sufﬁcient to repress the alternative lineage program
and to specify MPCs toward an endocrine/ductal or aci-
nar fate, respectively (62). Reciprocal repression between
Nkx6 factors and Ptf1a constitutes a bistable switch in
MPCs that governs the equilibrium between endocrine and
acinar cell neogenesis and is thus crucial for normal cell
differentiation.
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SECONDARY PROGENITORS
At e13.5, during the midpoint of the branching phase of
pancreas development, a window of major cell differenti-
ation begins, known as the secondary transition (2). Over
the next three days, all ﬁve endocrine cell types arise: the
b, a, d, e, and pancreatic polypeptide (PP) cells, which,
respectively, synthesize and secrete the endocrine hor-
mones insulin, glucagon, somatostatin, ghrelin, and pan-
creatic polypeptide.
While the existence of MPCs during early pancreas or-
ganogenesis is beyond contention, it is only now becoming
established whether such a cell population persists later in
development and if so, where they reside. During the sec-
ondary transition, the early MPC marker Sox9 becomes
restricted to the embryonic ductal tree within which Ngn3
1
endocrine progenitor cells are intercalated (55) (Fig. 2).
Short-term Sox9-eGFP-based lineage-tracing revealed that
from e15.5 until birth, endocrine cells arise from Sox9
1 cells
via transient hormone
- Ngn3
1 endocrine progenitor cells
(63). eGFP labeling similarly showed a proportion of acinar
cells to arise from Sox9
1 cells at the onset of the secondary
transition although, unlike endocrine cells, the acinar com-
partment appears to expand predominantly through pro-
liferation in late embryogenesis (63). Subsequent recent
genetic lineage-labeling studies in mice expressing Cre-ER
T2
driven by the promoters of either ductally expressed Hnf1b
(61) or Mucin1 (Muc1) (64) have largely corroborated these
ﬁndings, showing secondary transition ductal cells to give
rise to endocrine cells via Ngn3
1 endocrine progenitors, as
well as differentiated ductal cells. Taken together, these
studies support the existence of a Sox9
1 Hnf1b
1 Muc1
1
secondary progenitor cell population comprising the em-
bryonic ductal tree (thus, recently coined progenitor cords)
(Fig. 2). Future work is required to determine 1)w h e t h e r
individual secondary progenitors are multipotent and 2)i f
lineage-restricted, whether they are committed to distinct
fates dependent upon their location (distal vs. proximal)
within the ductal tree.
SIGNALS REGULATING ENDOCRINE VERSUS ACINAR
DIFFERENTIATION
Findings from early tissue recombination experiments (65)
that the pancreatic mesenchyme promotes acinar differen-
tiation in the pancreatic epithelium, led to the notion that
the pancreatic epithelium forms endocrine tissue by “de-
fault” (66). Subsequent work has shown that at e12.5, while
the mesenchyme is necessary for acinar differentiation, it
represses the endocrine program (67). Both effects are
reproduced by the antagonist of the TGF-b ligand activin B,
follistatin, which is expressed in e12.5 pancreatic mesen-
chyme (68). Examination of temporally inducible mouse
models for both abrogation or hyperactivation of the TGF-b
signaling pathway in the pancreatic mesenchyme and/or
epithelium will be needed to dissect how this pathway
inﬂuences the endocrine program.
Recent work has reinforced the notion that mesenchyme-
derived extracellular matrix components, such as laminin-1,
promote acinar cell development (36). Inhibition of lam-
inin-1 translation has been shown to abrogate acinar dif-
ferentiation of pancreatic epithelial cells while exerting no
inﬂuence on endocrine differentiation (69,70). Concor-
dantly, the disintegration of the pancreatic epithelium in
the absence of Cdc42 results in enhanced epithelial expo-
sure to pancreatic mesenchyme and laminin-1, manifesting
in increased acinar differentiation at the expense of endo-
crine and ductal differentiation (36). Moreover, antibody-
mediated inhibition of laminin-1 function in Cdc42-deﬁcient
pancreatic explants signiﬁcantly reduces acinar cell differ-
entiation, conﬁrming the proacinar activity of mesenchymal
laminin-1 (36).
A similar role has been suggested for FGF signals from
the mesenchyme: the FGFR2b ligands FGFs 1, 7, and 10 all
favor acinar cell development (71). While it is still unclear
whether the mesenchyme is a relevant source of Wnt
proteins, evidence suggests that canonical Wnt signaling in
the pancreatic epithelium also promotes acinar growth
(56,72). A role for Wnt signaling in endocrine differentiation
is, however, contentious: Pdx1-Cre-mediated b-catenin de-
letion has been shown by some (73) to decrease b-cell
numbers, but not by others (56,72). This discrepancy
may be contingent on the Pdx1-Cre line used. Reporter-
monitored, temporally inducible, and efﬁcient ablation of
b-catenin in pancreatic epithelium will be required to
comprehensively establish the precise role of Wnt signal-
ing in endocrine differentiation.
SPECIFYING THE FIVE ENDOCRINE LINEAGES
Ngn3 induces endocrine commitment. Expression of
Ngn3 in pancreatic progenitors has been shown to be cru-
cial for inducing commitment to the endocrine lineage in
a cell-autonomous manner (51). While Ngn3 is expressed in
pancreatic buds by e9.5, expression does not peak until the
secondary transition after which it is progressively down-
regulated to almost undetectable levels in differentiated
endocrine cells (51,74,75). Lineage-tracing studies have
shown that Ngn3
1 cells are pan-endocrine progenitors giv-
ing rise to all ﬁve endocrine cell types in the pancreas (37)
(Fig. 3). Recent studies have further revealed that a high
Ngn3 expression level is critical for this endocrine com-
mitment. While lowered Ngn3 gene dosage in mice hetero-
zygous or hypomorphic for Ngn3 results in elevated
numbers of Ngn3
1 pancreatic progenitors, some of these
(likely low) Ngn3-expressing cells are misallocated to ductal
or acinar fates (76). When extended to a single-cell level,
however, results of a recent in vivo clonal analysis suggest
individual Ngn3
1 cells to be unipotent, with each Ngn3
1 cell
being the precursor of a single endocrine cell (77). This
ﬁnding is, however, inconsistent with the currently prevail-
ing model of endocrine cell subtype speciﬁcation (Fig. 3
Model A) to be discussed later. Concordant with Ngn3
1
cells being panendocrine progenitors, Ngn3-nullizygous
mice exhibit a complete loss of all endocrine cells in both
pancreas (74) and intestine (78,79) while in contrast, gastric
endocrine cell development in the glandular stomach is only
partly abrogated (79,80). Surprisingly, however, presumptive
Ngn3 null mutations in humans manifest only in loss of in-
testinal endocrine cells (81), hinting at divergent mecha-
nisms for pancreatic endocrine cell speciﬁcation between
mouse and human.
In vivo, the competence of progenitors to generate the
distinct endocrine cell types changes throughout the
course of pancreatic development and is autonomous to
the pancreatic epithelium (82). Temporally inducible ex-
pression of Ngn3 in Pdx1
1 progenitors of Ngn3
2/2 mice
has revealed that progressively later Ngn3 activation
induces ﬁrst glucagon
1 cells, then insulin
1 cells, PP
1 cells,
and ﬁnally somatostatin
1 cells (82). Attempts to dissect
the mechanism(s) governing adoption of a given endocrine
lineage by Ngn3
1 progenitors have largely focused upon
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is important to consider that the timing of endocrine sub-
type speciﬁcation relative to Ngn3 activation remains un-
known (77), thus illustrating the need for studies focusing
on the speciﬁc timing of cell fate speciﬁcation as well as
the identiﬁcation of temporally and spatially constrained
cues (both cell-intrinsic and -extrinsic) that affect endo-
crine subtype choices.
DOWNSTREAM TARGETS OF NGN3
While it is still unclear whether islet cell type speciﬁcation
occurs prior to Ngn3 induction, manipulation of tran-
scriptional programs downstream of Ngn3 has provided
insight into the molecular control of islet cell terminal
differentiation. Moreover, these studies have revealed that
considerable plasticity between the ﬁve endocrine cell
types still exists after Ngn3 expression has been initiated.
The zinc-ﬁnger transcription factor Ia1 (Insm1) was
identiﬁed as a direct transcriptional target gene of Ngn3
(83). Mice deﬁcient for Ia1, which is coexpressed with
Ngn3 in both endocrine progenitor cells and some differ-
entiated endocrine cells (83,84), exhibit impaired terminal
differentiation of a-a n db-cells as well as gut enter-
oendocrine cells associated with downregulation of tran-
scription factors that promote b-cell differentiation (84).
How Ngn3-induced Ia1 activation initiates the endocrine
program is currently unknown. Further work will be nec-
essary to determine whether Ia1 functions in the endocrine
pancreas as a transcriptional repressor as biochemical
studies indicate (85).
During pancreas development, NeuroD1 (Beta2) is
expressed from e9.5 in a partially overlapping manner with
Ia1 in differentiating and mature endocrine cells (83,86);
concordantly, NeuroD1 deﬁciency in mice results in gen-
eration of hypoplastic, disorganized islets, probably be-
cause of perturbed endocrine survival and differentiation
(86). Intriguingly, inactivation of Ia1 (84) or NeuroD1 (86)
phenocopies the enteroendocrine dysgenesis of Ngn3
2/2
mice, alluding to parallels between transcriptional pro-
grams governing endocrine differentiation in pancreas and
gut.
Both Nkx2.2 and Pax4 are expressed in pancreatic epi-
thelium by e9.5; while Nkx2.2 thereafter becomes re-
stricted to a-, b-, and PP-cells (87), Pax4 becomes conﬁned
to b- and d-cells (88). Intriguingly, without Nkx2.2, b-cells
are lost and numbers of a- and PP-cells reduced while the
normally scarce ghrelin
1 e-cell population is greatly ex-
panded (87,89). Similarly, inactivation of Pax4 also mani-
fests in a loss of b-cells and expansion of the ghrelin
1
population (88,89), but unlike Nkx2.2 mutants, ghrelin
1
cells in Pax4-deﬁcient mice coexpress glucagon (90).
These studies demonstrate that Nkx2.2 and Pax4 are both
crucially required for development of the b-cell lineage.
Consistent with this notion, recent studies have revealed
that the ectopic expression of Pax4 in the early pancreas,
endocrine compartment, or even a-cells, forces the adop-
tion of a b-cell fate, showing Pax4 to be both necessary
and sufﬁcient to promote b-cell lineage commitment (91).
In vitro studies have suggested Nkx2.2 to directly regu-
late Nkx6.1 (92); concordantly, Nkx2.2; Nkx6.1 compound
nullizygous mutants exhibit similar changes in endocrine
FIG. 3. Alternative models of endocrine subtype speciﬁcation from endocrine progenitor cells. Model A: Prevailing model of endocrine subtype
speciﬁcation in wild-type, Arx
2/2, Pax4
2/2, and compound Arx
2/2; Pax4
2/2 mutants, based on the assumption that cells make binary fate decisions
involving an intermediary hypothetical b-/d-cell precursor cell downstream of Ngn3. Model B: Alternative model in which Arx and Pax4 function to
stabilize lineage decisions downstream of Ngn3. Note that PP- and e-cell populations are excluded for the sake of clarity.
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2/2 mice, suggesting a
function for Nkx6.1 downstream of Nkx2.2 (93). Nkx6.1 is
broadly expressed in the pancreatic epithelium from e9.0,
is later expressed in endocrine progenitors, then sub-
sequently becomes b-cell–restricted (93). Unlike Nkx2.2
mutants, Nkx6.1-null mice speciﬁcally lose only the b-cell
lineage (93). The b-cell loss in Nkx6.1-deﬁcient mice could,
however, also be secondary to the early endocrine to aci-
nar cell fate switch caused by Nkx6.1 abrogation in MPCs
(62), thus illustrating the general limitation of studying
speciﬁc gene functions in null mutant animals. The spe-
ciﬁc role of Nkx6.1 in b-cell speciﬁcation/differentiation
remains to be deﬁned and will require conditional gene
inactivation in a temporally and spatially regulated
manner.
The recent dissection of the role played by Arx in en-
docrine cell development has yielded insight into the
mechanisms regulating the segregation of the a- and b-cell
lineages. Arx is expressed in a Ngn3-dependent fashion
from e9.5 in the pancreas whereafter its expression
becomes conﬁned to a- and PP-cells (94,95). Abrogation of
Arx activity causes a-cell deﬁciency while numbers of
b-a n dd-cells are increased (94), revealing Arx to be both
required for a-cell fate acquisition and repression of b- and
d-cell fate, the mirror opposite of the role of Pax4 with
which Arx is coexpressed during early endocrine differ-
entiation. Concordantly, ectopic Arx expression in the
endocrine precursors or mature b-cells expands a- and
PP-cell numbers at the expense of b-cells (95), showing
Arx to be both necessary and sufﬁcient to promote a- and
PP-lineage commitment. These ﬁndings are consistent with
studies showing that Pax4 and Arx mutually and directly
inhibit one another’s transcription at the promoter level
(96). The observation that both a- and b-cells in Pax4; Arx
compound mutant mice are replaced by d-cells, which
later initiate ectopic PP expression (96), has led to a re-
ﬁnement of the model by which Pax4/Arx govern islet cell
subtype choices downstream of Ngn3. Namely, it has been
proposed that when one of the two factors is activated in
preference to the other in endocrine progenitors, Arx
speciﬁes a-cell fate while Pax4 ﬁrst permits commitment
toward a b-/d-cell fate by repressing Arx then subsequently
driving a hypothetical bipotential b-/d-cell precursor cell
toward a b-cell fate (96) (Fig. 3 Model A). This prevailing
model is based on the assumption that two cells with dif-
ferent endocrine subtype identity arise from an inter-
mediary progenitor downstream of Ngn3, which is in
apparent contradiction to the recent observation that each
Ngn3
1 cell only gives rise to one endocrine cell and is
therefore unipotent (77). Reconciling this apparent con-
tradiction, an alternative explanation for the observed
phenotypes is that Arx and Pax4 function to stabilize lin-
eage decisions downstream of Ngn3 rather than reallo-
cating cells at the level of a hypothetical intermediate
precursor cell (Fig. 3 Model B). Additional studies are
clearly required to determine when and how endocrine
subtype identity is established and stabilized during de-
velopment.
Similar to Arx and Pax4, most recently, loss-of-function
studies in both mouse (97) and zebraﬁsh (98) have in-
triguingly hinted at a role for the transcription factor Rfx6
in controlling endocrine cell subtype choice. Rfx6, which
is activated by Ngn3, is expressed broadly throughout the
epithelium of the mouse gut by e9.0 and within a subset of
endocrine progenitor cells during the secondary transition,
becoming restricted to islet cells by adulthood (97,98).
Rfx6 exhibits a parallel expression pattern in zebraﬁsh
pancreas (98). Consistent with its endocrine expression,
mice lacking Rfx6 exhibit a loss of all mature endo-
crine cell types with the notable exception of the PP-cells,
which unusually express the b-cell marker Nkx6.1 (97).
In zebraﬁsh, Rfx6 abrogation results in failure of the
non–b-cell endocrine lineages to differentiate from endo-
crine progenitors while the b-cells fail to coalesce into an
islet (98). Future studies will be needed to determine the
speciﬁc roles played by Rfx6 in the transcription factor
network orchestrating endocrine differentiation.
ISLET FORMATION AND b-CELL MATURATION
As birth nears, the exocrine pancreas grows rapidly, pri-
marily through mitotic expansion of differentiated acinar
cells. Meanwhile, from e16.5 onwards, the endocrine cells
coalesce into polyclonal clusters to form functional islets
that, in the mouse, comprise a central core of b-cells and
an outer mantle composed of the other four endocrine cell
types. Disrupted islet cytoarchitecture following b-cell–
speciﬁc deletion of cadherins or neural cell adhesion mole-
cule has revealed a requirement for cell adhesion molecules
in b-cell–b-cell adhesion during islet formation (99,100). In
addition, in vitro evidence (101) supports a role for matrix
metalloproteinase enzymes in facilitating endocrine cell mi-
gration via extracellular matrix degradation. However, this
hypothesis has not been borne out in vivo (102).
During the early postnatal period, the b-cells acquire the
ability to regulate insulin secretion in response to glucose
(103), requiring the expression of the glucose transporter
Glut2 and prohormone convertase PC1/3 to cleave pro-
insulin to active insulin. The recent characterization of the
roles played by the transcription factors MafA and MafB in
pancreas development has offered insight into the mech-
anisms governing b-cell terminal differentiation. MafA,
which was initially identiﬁed as a b-cell–speciﬁc activator
of insulin transcription (reviewed in [104]), is exclusively
expressed in insulin
1 cells from e13.5 onward (105). In
contrast, MafB is expressed in both insulin
1 and gluca-
gon
1 cells by e12.5 but becomes restricted postnatally
to a-cells (106). Thus, maturing b-cells undergo a devel-
opmental MafB→MafA switch (107). Apparently conﬂict-
ing with its expression in immature insulin
1 cells, MafA
function is dispensable for b-cell development, most likely
because of functional compensation by MafB (108). How-
ever, deletion of MafB reduces numbers of insulin
1 and
glucagon
1 cells and delays the development of insulin
1
cells until the onset of MafA expression (109). Loss of MafB
is associated with downregulation of factors required for
b-cell maturation and function such as Pdx1, MafA, Nkx6.1,
and Glut2. MafB is thus crucially required for the terminal
differentiation of both a-a n db-cells by acting as a master
activator of hormone gene transcription and key regulators
of b-cell differentiation and function.
Serving as a potent example of individual transcription
factors exhibiting multiple roles during pancreatic devel-
opment, conditional deletion of Isl1 has recently un-
masked a crucial requirement for this transcription factor
in endocrine cell maturation (110). Ablation of Isl1 im-
mediately prior to the secondary transition results in a se-
vere reduction in the number of mature endocrine cells
prior to the eventual loss of endocrine cell mass con-
tributed by the changes in cell proliferation and survival
(110). Paralleling the multiple roles played by Isl1 in pan-
creatic organogenesis, recent studies have also uncovered
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NeuroD1, in the acquisition and maintenance of the termi-
nally differentiated, fully functional b-cell phenotype
(75,111). Future work will undoubtedly focus on further
elucidating the roles of Isl1 and other endocrine differenti-
ation factors in b-cell maintenance and function as the
requisite genetic tools become available.
FUTURE PERSPECTIVES
Despite the wealth of knowledge we have amassed to date,
many questions in the ﬁeld of pancreas and b-cell de-
velopment remain unanswered, as this review has sought
to illustrate. It is only relatively recently, for example, that
evolving transgenic mouse technology has provided in-
sight into the roles of transcription factors such as Ptf1a
and Sox17 in allocating pancreatic fate at the expense of
other endodermally derived organs. The inability of any
single gene deletion to prevent formation of the early
pancreatic anlage hints at the complexity of the tran-
scriptional network governing this process and the in-
volvement of as yet unidentiﬁed players, which further
work will undoubtedly unmask. How known transcriptional
regulators interact with one another and with extraneous
signaling pathways is also ripe for future examination,
whether in the control of pancreatic speciﬁcation, growth,
or cytodifferentiation.
Outstanding among current questions in the ﬁeld is the
issue of multipotency of individual progenitors at single-
cell resolution. This area of investigation would greatly
beneﬁt from the development of a culture system in which
organ development can be initiated from single cells in
vitro, as recently established for cells in the intestinal
crypts (112). Another still understudied area is the ques-
tion of whether or how the physical location of cells in the
developing pancreas bestows lineage-restriction upon
progenitors. Open questions include whether all ductal
cells in the secondary transition progenitor cords function
as progenitor cells; whether such progenitors are homo-
geneously or heterogeneously lineage-restricted; and if the
latter, the factor(s) governing progenitor commitment or
differentiation into ductal, endocrine, or acinar lineages.
Finally, as illustrated in this review, we still know very
little about when and how the ﬁve different endocrine cell
subtypes are speciﬁed during development. It is antici-
pated that much effort will be expended in the future with
the goal of answering some of these questions. It is hoped
that acquiring more comprehensive insight into the pro-
cesses governing b-cell neogenesis in vivo will enable the
in vitro generation of unlimited quantities of functional
insulin-producing cells for the successful management and
eventual cure of diabetes.
ACKNOWLEDGMENTS
This work is supported by grants from the Juvenile
Diabetes Research Foundation, the National Institutes of
Health (NIH) National Institute of Diabetes and Digestive
and Kidney Diseases, and The NIH b Cell Biology Consor-
tium (BCBC).
No potential conﬂicts of interest relevant to this article
were reported.
P.A.S. researched data and wrote the manuscript. M.S.
reviewed and edited the manuscript and contributed to
discussion.
We thank our colleagues, whose work is cited here, for
their contributions and apologize to all of those whose
references were omitted due to space constraints. We are
also grateful to members of the Sander laboratory for
constructive comments on the manuscript.
REFERENCES
1. D’Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hor-
mone-expressing endocrine cells from human embryonic stem cells. Nat
Biotechnol 2006;24:1392–1401
2. Pictet RL, Clark WR, Williams RH, Rutter WJ. An ultrastructural analysis
of the developing embryonic pancreas. Dev Biol 1972;29:436–467
3. Hebrok M, Kim SK, St Jacques B, McMahon AP, Melton DA. Regulation of
pancreas development by hedgehog signaling. Development 2000;127:
4905–4913
4. Kim SK, Hebrok M, Melton DA. Notochord to endoderm signaling is re-
quired for pancreas development. Development 1997;124:4243–4252
5. Kim SK, Melton DA. Pancreas development is promoted by cyclopamine,
a hedgehog signaling inhibitor. Proc Natl Acad Sci USA 1998;95:13036–
13041
6. Hebrok M, Kim SK, Melton DA. Notochord repression of endodermal
Sonic hedgehog permits pancreas development. Genes Dev 1998;12:1705–
1713
7. Wandzioch E, Zaret KS. Dynamic signaling network for the speciﬁcation
of embryonic pancreas and liver progenitors. Science 2009;324:1707–
1710
8. Stafford D, Prince VE. Retinoic acid signaling is required for a critical
early step in zebraﬁsh pancreatic development. Curr Biol 2002;12:1215–
1220
9. Chen Y, Pan FC, Brandes N, Afelik S, Sölter M, Pieler T. Retinoic acid
signaling is essential for pancreas development and promotes endocrine
at the expense of exocrine cell differentiation in Xenopus. Dev Biol 2004;
271:144–160
10. Martín M, Gallego-Llamas J, Ribes V, et al. Dorsal pancreas agenesis in
retinoic acid-deﬁcient Raldh2 mutant mice. Dev Biol 2005;284:399–411
11. Molotkov A, Molotkova N, Duester G. Retinoic acid generated by Raldh2
in mesoderm is required for mouse dorsal endodermal pancreas de-
velopment. Dev Dyn 2005;232:950–957
12. Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation
by signals from blood vessels. Science 2001;294:564–567
13. Yoshitomi H, Zaret KS. Endothelial cell interactions initiate dorsal pan-
creas development by selectively inducing the transcription factor Ptf1a.
Development 2004;131:807–817
14. Jacquemin P, Yoshitomi H, Kashima Y, Rousseau GG, Lemaigre FP, Zaret KS.
An endothelial-mesenchymal relay pathway regulates early phases of
pancreas development. Dev Biol 2006;290:189–199
15. Kinkel MD, Eames SC, Alonzo MR, Prince VE. Cdx4 is required in the
endoderm to localize the pancreas and limit beta-cell number. De-
velopment 2008;135:919–929
16. Asayesh A, Sharpe J, Watson RP, et al. Spleen versus pancreas: strict
control of organ interrelationship revealed by analyses of Bapx1-/- mice.
Genes Dev 2006;20:2208–2213
17. Bort R, Martinez-Barbera JP, Beddington RS, Zaret KS. Hex homeobox
gene-dependent tissue positioning is required for organogenesis of the
ventral pancreas. Development 2004;131:797–806
18. Guz Y, Montminy MR, Stein R, et al. Expression of murine STF-1, a pu-
tative insulin gene transcription factor, in beta cells of pancreas, duo-
denal epithelium and pancreatic exocrine and endocrine progenitors
during ontogeny. Development 1995;121:11–18
19. Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic
mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/
PDX1-deﬁcient mice. Development 1996;122:1409–1416
20. Ofﬁeld MF, Jetton TL, Labosky PA, et al. PDX-1 is required for pancreatic
outgrowth and differentiation of the rostral duodenum. Development
1996;122:983–995
21. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV.
The role of the transcriptional regulator Ptf1a in converting intestinal to
pancreatic progenitors. Nat Genet 2002;32:128–134
22. Krapp A, Knöﬂer M, Frutiger S, Hughes GJ, Hagenbüchle O, Wellauer PK.
The p48 DNA-binding subunit of transcription factor PTF1 is a new
exocrine pancreas-speciﬁc basic helix-loop-helix protein. EMBO J 1996;
15:4317–4329
23. Krapp A, Knöﬂer M, Ledermann B, et al. The bHLH protein PTF1-p48 is
essential for the formation of the exocrine and the correct spatial orga-
nization of the endocrine pancreas. Genes Dev 1998;12:3752–3763
24. Burlison JS, Long Q, Fujitani Y, Wright CV, Magnuson MA. Pdx-1 and
Ptf1a concurrently determine fate speciﬁcation of pancreatic multipotent
progenitor cells. Dev Biol 2008;316:74–86
CURRENT PERSPECTIVES IN b-CELL DEVELOPMENT
374 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.org25. Afelik S, Chen Y, Pieler T. Combined ectopic expression of Pdx1 and
Ptf1a/p48 results in the stable conversion of posterior endoderm into
endocrine and exocrine pancreatic tissue. Genes Dev 2006;20:1441–1446
26. Spence JR, Lange AW, Lin SC, et al. Sox17 regulates organ lineage seg-
regation of ventral foregut progenitor cells. Dev Cell 2009;17:62–74
27. Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH. Pancreas dorsal lobe
agenesis and abnormal islets of Langerhans in Hlxb9-deﬁcient mice. Nat
Genet 1999;23:71–75
28. Li H, Arber S, Jessell TM, Edlund H. Selective agenesis of the dorsal
pancreas in mice lacking homeobox gene Hlxb9. Nat Genet 1999;23:67–70
29. Murtaugh LC. Pancreas and beta-cell development: from the actual to the
possible. Development 2007;134:427–438
30. Wu KL, Gannon M, Peshavaria M, et al. Hepatocyte nuclear factor 3beta is
involved in pancreatic beta-cell-speciﬁc transcription of the pdx-1 gene.
Mol Cell Biol 1997;17:6002–6013
31. Jacquemin P, Lemaigre FP, Rousseau GG. The Onecut transcription
factor HNF-6 (OC-1) is required for timely speciﬁcation of the pancreas
and acts upstream of Pdx-1 in the speciﬁcation cascade. Dev Biol 2003;
258:105–116
32. Lee CS, Sund NJ, Behr R, Herrera PL, Kaestner KH. Foxa2 is required
for the differentiation of pancreatic alpha-cells. Dev Biol 2005;278:484–495
33. Jacquemin P, Durviaux SM, Jensen J, et al. Transcription factor hepato-
cyte nuclear factor 6 regulates pancreatic endocrine cell differentiation
and controls expression of the proendocrine gene ngn3. Mol Cell Biol
2000;20:4445–4454
34. Haumaitre C, Barbacci E, Jenny M, Ott MO, Gradwohl G, Cereghini S.
Lack of TCF2/vHNF1 in mice leads to pancreas agenesis. Proc Natl Acad
Sci USA 2005;102:1490–1495
35. Kumar M, Melton D. Pancreas speciﬁcation: a budding question. Curr
Opin Genet Dev 2003;13:401–407
36. Kesavan G, Sand FW, Greiner TU, et al. Cdc42-mediated tubulogenesis
controls cell speciﬁcation. Cell 2009;139:791–801
37. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic
lineage: NGN31 cells are islet progenitors and are distinct from duct
progenitors. Development 2002;129:2447–2457
38. Chiang MK, Melton DA. Single-cell transcript analysis of pancreas de-
velopment. Dev Cell 2003;4:383–393
39. Stanger BZ, Tanaka AJ, Melton DA. Organ size is limited by the number of
embryonic progenitor cells in the pancreas but not the liver. Nature 2007;
445:886–891
40. Golosow N, Grobstein C. Epitheliomesenchymal interaction in pancreatic
morphogenesis. Dev Biol 1962;4:242–255
41. Wessells NK, Cohen JH. Early pancreas organogenesis: morphogenesis,
tissue interactions, and mass effects. Dev Biol 1967;15:237–270
42. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent re-
quirement for ISL1 in formation of pancreatic mesenchyme and islet cells.
Nature 1997;385:257–260
43. Bhushan A, Itoh N, Kato S, et al. Fgf10 is essential for maintaining the
proliferative capacity of epithelial progenitor cells during early pancreatic
organogenesis. Development 2001;128:5109–5117
44. Pulkkinen MA, Spencer-Dene B, Dickson C, Otonkoski T. The IIIb iso-
form of ﬁbroblast growth factor receptor 2 is required for proper growth
and branching of pancreatic ductal epithelium but not for differentiation
of exocrine or endocrine cells. Mech Dev 2003;120:167–175
45. Norgaard GA, Jensen JN, Jensen J. FGF10 signaling maintains the pan-
creatic progenitor cell state revealing a novel role of Notch in organ
development. Dev Biol 2003;264:323–338
46. Jonckheere N, Mayes E, Shih HP, et al. Analysis of mPygo2 mutant mice
suggests a requirement for mesenchymal Wnt signaling in pancreatic
growth and differentiation. Dev Biol 2008;318:224–235
47. Ahnfelt-Rønne J, Ravassard P, Pardanaud-Glavieux C, Scharfmann R,
Serup P. Mesenchymal bone morphogenetic protein signaling is required
for normal pancreas development. Diabetes 2010;59:1948–1956
48. Jessen S, Gu B, Dai X. Pygopus and the Wnt signaling pathway: a diverse
set of connections. Bioessays 2008;30:448–456
49. Georgia S, Soliz R, Li M, Zhang P, Bhushan A. p57 and Hes1 coordinate
cell cycle exit with self-renewal of pancreatic progenitors. Dev Biol 2006;
298:22–31
50. Jensen J, Pedersen EE, Galante P, et al. Control of endodermal endocrine
development by Hes-1. Nat Genet 2000;24:36–44
51. Apelqvist A, Li H, Sommer L, et al. Notch signalling controls pancreatic
cell differentiation. Nature 1999;400:877–881
52. Fujikura J, Hosoda K, Iwakura H, et al. Notch/Rbp-j signaling prevents
premature endocrine and ductal cell differentiation in the pancreas. Cell
Metab 2006;3:59–65
53. Lee JC, Smith SB, Watada H, et al. Regulation of the pancreatic pro-
endocrine gene neurogenin3. Diabetes 2001;50:928–936
54. Esni F, Ghosh B, Biankin AV, et al. Notch inhibits Ptf1 function and acinar
cell differentiation in developing mouse and zebraﬁsh pancreas. De-
velopment 2004;131:4213–4224
55. Seymour PA, Freude KK, Tran MN, et al. SOX9 is required for mainte-
nance of the pancreatic progenitor cell pool. Proc Natl Acad Sci USA
2007;104:1865–1870
56. Murtaugh LC, Law AC, Dor Y, Melton DA. Beta-catenin is essential for
pancreatic acinar but not islet development. Development 2005;132:4663–
4674
57. Papadopoulou S, Edlund H. Attenuated Wnt signaling perturbs pancreatic
growth but not pancreatic function. Diabetes 2005;54:2844–2851
58. Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M. Stabilization
of beta-catenin impacts pancreas growth. Development 2006;133:2023–
2032
59. Heller RS, Klein T, Ling Z, et al. Expression of Wnt, Frizzled, sFRP, and
DKK genes in adult human pancreas. Gene Expr 2003;11:141–147
60. Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, Melton DA. A
multipotent progenitor domain guides pancreatic organogenesis. Dev Cell
2007;13:103–114
61. Solar M, Cardalda C, Houbracken I, et al. Pancreatic exocrine duct cells
give rise to insulin-producing beta cells during embryogenesis but not
after birth. Dev Cell 2009;17:849–860
62. Schaffer AE, Freude KK, Nelson SB, Sander M. Nkx6 transcription factors
and Ptf1a function as antagonistic lineage determinants in multipotent
pancreatic progenitors. Dev Cell 2010;18:1022–1029
63. Seymour PA, Freude KK, Dubois CL, Shih HP, Patel NA, Sander M. A
dosage-dependent requirement for Sox9 in pancreatic endocrine cell
formation. Dev Biol 2008;323:19–30
64. Kopinke D, Murtaugh LC. Exocrine-to-endocrine differentiation is de-
tectable only prior to birth in the uninjured mouse pancreas. BMC Dev
Biol 2010;10:38
65. Rutter WJ, Pictet RL, Harding JD, Chirgwin JM, MacDonald RJ, Przybyla AE.
An analysis of pancreatic development: role of mesenchymal factor and
other extracellular factors. Symp Soc Dev Biol 1978;35:205–227
66. Gittes GK, Galante PE, Hanahan D, Rutter WJ, Debase HT. Lineage-spe-
ciﬁc morphogenesis in the developing pancreas: role of mesenchymal
factors. Development 1996;122:439–447
67. Duvillié B, Attali M, Bounacer A, Ravassard P, Basmaciogullari A,
Scharfmann R. The mesenchyme controls the timing of pancreatic beta-
cell differentiation. Diabetes 2006;55:582–589
68. Miralles F, Czernichow P, Scharfmann R. Follistatin regulates the relative
proportions of endocrine versus exocrine tissue during pancreatic de-
velopment. Development 1998;125:1017–1024
69. Crisera CA, Kadison AS, Breslow GD, Maldonado TS, Longaker MT,
Gittes GK. Expression and role of laminin-1 in mouse pancreatic organ-
ogenesis. Diabetes 2000;49:936–944
70. Li Z, Manna P, Kobayashi H, et al. Multifaceted pancreatic mesenchymal
control of epithelial lineage selection. Dev Biol 2004;269:252–263
71. Miralles F, Czernichow P, Ozaki K, Itoh N, Scharfmann R. Signaling
through ﬁbroblast growth factor receptor 2b plays a key role in the de-
velopment of the exocrine pancreas. Proc Natl Acad Sci USA 1999;96:
6267–6272
72. Wells JM, Esni F, Boivin GP, et al. Wnt/beta-catenin signaling is required
for development of the exocrine pancreas. BMC Dev Biol 2007;7:4
73. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A. Pancreas-speciﬁc
deletion of beta-catenin reveals Wnt-dependent and Wnt-independent
functions during development. Curr Biol 2005;15:1677–1683
74. Gradwohl G, Dierich A, LeMeur M, Guillemot F. neurogenin3 is required
for the development of the four endocrine cell lineages of the pancreas.
Proc Natl Acad Sci USA 2000;97:1607–1611
75. Wang S, Jensen JN, Seymour PA, et al. Sustained Neurog3 expression in
hormone-expressing islet cells is required for endocrine maturation and
function. Proc Natl Acad Sci USA 2009;106:9715–9720
76. Wang S, Yan J, Anderson DA, et al. Neurog3 gene dosage regulates al-
location of endocrine and exocrine cell fates in the developing mouse
pancreas. Dev Biol 2010;339:26–37
77. Desgraz R, Herrera PL. Pancreatic neurogenin 3-expressing cells are
unipotent islet precursors. Development 2009;136:3567–3574
78. Mellitzer G, Beucher A, Lobstein V, et al. Loss of enteroendocrine cells in
mice alters lipid absorption and glucose homeostasis and impairs post-
natal survival. J Clin Invest 2010;120:1708–1721
79. Jenny M, Uhl C, Roche C, et al. Neurogenin3 is differentially required for
endocrine cell fate speciﬁcation in the intestinal and gastric epithelium.
EMBO J 2002;21:6338–6347
80. Lee CS, Perreault N, Brestelli JE, Kaestner KH. Neurogenin 3 is essential for
the proper speciﬁcation of gastric enteroendocrine cells and the mainte-
nance of gastric epithelial cell identity. Genes Dev 2002;16:1488–1497
P.A. SEYMOUR AND M. SANDER
diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 37581. Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital
malabsorptive diarrhea. N Engl J Med 2006;355:270–280
82. Johansson KA, Dursun U, Jordan N, et al. Temporal control of neuro-
genin3 activity in pancreas progenitors reveals competence windows for
the generation of different endocrine cell types. Dev Cell 2007;12:457–465
83. Mellitzer G, Bonné S, Luco RF, et al. IA1 is NGN3-dependent and essential
for differentiation of the endocrine pancreas. EMBO J 2006;25:1344–1352
84. Gierl MS, Karoulias N, Wende H, Strehle M, Birchmeier C. The zinc-ﬁnger
factor Insm1 (IA-1) is essential for the development of pancreatic beta
cells and intestinal endocrine cells. Genes Dev 2006;20:2465–2478
85. Breslin MB, Zhu M, Notkins AL, Lan MS. Neuroendocrine differentiation
factor, IA-1, is a transcriptional repressor and contains a speciﬁc DNA-
binding domain: identiﬁcation of consensus IA-1 binding sequence. Nu-
cleic Acids Res 2002;30:1038–1045
86. Naya FJ, Huang HP, Qiu Y, et al. Diabetes, defective pancreatic mor-
phogenesis, and abnormal enteroendocrine differentiation in BETA2/
neuroD-deﬁcient mice. Genes Dev 1997;11:2323–2334
87. Sussel L, Kalamaras J, Hartigan-O’Connor DJ, et al. Mice lacking the
homeodomain transcription factor Nkx2.2 have diabetes due to arrested
differentiation of pancreatic beta cells. Development 1998;125:2213–2221
88. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene
is essential for differentiation of insulin-producing beta cells in the
mammalian pancreas. Nature 1997;386:399–402
89. Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L. Ghrelin
cells replace insulin-producing beta cells in two mouse models of pan-
creas development. Proc Natl Acad Sci USA 2004;101:2924–2929
90. Heller RS, Jenny M, Collombat P, et al. Genetic determinants of pancre-
atic epsilon-cell development. Dev Biol 2005;286:217–224
91. Collombat P, Xu X, Ravassard P, et al. The ectopic expression of Pax4 in
the mouse pancreas converts progenitor cells into alpha and sub-
sequently beta cells. Cell 2009;138:449–462
92. Watada H, Mirmira RG, Leung J, German MS. Transcriptional and trans-
lational regulation of beta-cell differentiation factor Nkx6.1. J Biol Chem
2000;275:34224–34230
93. Sander M, Sussel L, Conners J, et al. Homeobox gene Nkx6.1 lies
downstream of Nkx2.2 in the major pathway of beta-cell formation in the
pancreas. Development 2000;127:5533–5540
94. Collombat P, Mansouri A, Hecksher-Sorensen J, et al. Opposing actions of
Arx and Pax4 in endocrine pancreas development. Genes Dev 2003;17:
2591–2603
95. Collombat P, Hecksher-Sørensen J, Krull J, et al. Embryonic endocrine
pancreas and mature beta cells acquire alpha and PP cell phenotypes
upon Arx misexpression. J Clin Invest 2007;117:961–970
96. Collombat P, Hecksher-Sørensen J, Broccoli V, et al. The simultaneous
loss of Arx and Pax4 genes promotes a somatostatin-producing cell fate
speciﬁcation at the expense of the alpha- and beta-cell lineages in the
mouse endocrine pancreas. Development 2005;132:2969–2980
97. Smith SB, Qu HQ, Taleb N, et al. Rfx6 directs islet formation and insulin
production in mice and humans. Nature 2010;463:775–780
98. Soyer J, Flasse L, Raffelsberger W, et al. Rfx6 is an Ngn3-dependent
winged helix transcription factor required for pancreatic islet cell de-
velopment. Development 2010;137:203–212
99. Dahl U, Sjødin A, Semb H. Cadherins regulate aggregation of pancreatic
beta-cells in vivo. Development 1996;122:2895–2902
100. Esni F, Täljedal IB, Perl AK, Cremer H, Christofori G, Semb H. Neural cell
adhesion molecule (N-CAM) is required for cell type segregation and
normal ultrastructure in pancreatic islets. J Cell Biol 1999;144:325–337
101. Miralles F, Battelino T, Czernichow P, Scharfmann R. TGF-beta plays
a key role in morphogenesis of the pancreatic islets of Langerhans by
controlling the activity of the matrix metalloproteinase MMP-2. J Cell Biol
1998;143:827–836
102. Perez SE, Cano DA, Dao-Pick T, Rougier JP, Werb Z, Hebrok M. Matrix
metalloproteinases 2 and 9 are dispensable for pancreatic islet formation
and function in vivo. Diabetes 2005;54:694–701
103. Rozzo A, Meneghel-Rozzo T, Delakorda SL, Yang SB, Rupnik M. Exo-
cytosis of insulin: in vivo maturation of mouse endocrine pancreas. Ann
N Y Acad Sci 2009;1152:53–62
104. Oliver-Krasinski JM, Stoffers DA. On the origin of the beta cell. Genes Dev
2008;22:1998–2021
105. Matsuoka TA, Artner I, Henderson E, Means A, Sander M, Stein R. The
MafA transcription factor appears to be responsible for tissue-speciﬁc
expression of insulin. Proc Natl Acad Sci USA 2004;101:2930–2933
106. Artner I, Le Lay J, Hang Y, et al. MafB: an activator of the glucagon gene
expressed in developing islet alpha- and beta-cells. Diabetes 2006;55:297–
304
107. Nishimura W, Kondo T, Salameh T, et al. A switch from MafB to MafA
expression accompanies differentiation to pancreatic beta-cells. Dev Biol
2006;293:526–539
108. Zhang C, Moriguchi T, Kajihara M, et al. MafA is a key regulator of
glucose-stimulated insulin secretion. Mol Cell Biol 2005;25:4969–4976
109. Artner I, Blanchi B, Raum JC, et al. MafB is required for islet beta cell
maturation. Proc Natl Acad Sci USA 2007;104:3853–3858
110. Du A, Hunter CS, Murray J, et al. Islet-1 is required for the maturation,
proliferation, and survival of the endocrine pancreas. Diabetes 2009;58:
2059–2069
111. Gu C, Stein GH, Pan N, et al. Pancreatic beta cells require NeuroD to
achieve and maintain functional maturity. Cell Metab 2010;11:298–310
112. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-
villus structures in vitro without a mesenchymal niche. Nature 2009;459:
262–265
113. Kanai-Azuma M, Kanai Y, Gad JM, et al. Depletion of deﬁnitive gut en-
doderm in Sox17-null mutant mice. Development 2002;129:2367–2379
114. Monaghan AP, Kaestner KH, Grau E, Schütz G. Postimplantation ex-
pression patterns indicate a role for the mouse forkhead/HNF-3 alpha,
beta and gamma genes in determination of the deﬁnitive endoderm,
chordamesoderm and neuroectoderm. Development 1993;119:567–578
115. Cockell M, Stolarczyk D, Frutiger S, Hughes GJ, Hagenbüchle O, Wellauer
PK. Binding sites for hepatocyte nuclear factor 3 beta or 3 gamma and
pancreas transcription factor 1 are required for efﬁcient expression of
the gene encoding pancreatic alpha-amylase. Mol Cell Biol 1995;15:1933–
1941
116. Ang SL, Rossant J. HNF-3 beta is essential for node and notochord for-
mation in mouse development. Cell 1994;78:561–574
117. Weinstein DC, Ruiz i Altaba A, Chen WS, et al. The winged-helix tran-
scription factor HNF-3 beta is required for notochord development in the
mouse embryo. Cell 1994;78:575–588
118. Sund NJ, Vatamaniuk MZ, Casey M, et al. Tissue-speciﬁc deletion of
Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia.
Genes Dev 2001;15:1706–1715
119. Landry C, Clotman F, Hioki T, et al. HNF-6 is expressed in endoderm
derivatives and nervous system of the mouse embryo and participates to
the cross-regulatory network of liver-enriched transcription factors. Dev
Biol 1997;192:247–257
120. Rausa F, Samadani U, Ye H, et al. The cut-homeodomain transcriptional
activator HNF-6 is coexpressed with its target gene HNF-3 beta in the
developing murine liver and pancreas. Dev Biol 1997;192:228–246
121. Maestro MA, Boj SF, Luco RF, et al. Hnf6 and Tcf2 (MODY5) are linked in
a gene network operating in a precursor cell domain of the embryonic
pancreas. Hum Mol Genet 2003;12:3307–3314
122. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in
Pdx11/- mice. J Clin Invest 2003;111:1147–1160
123. Fukuda A, Kawaguchi Y, Furuyama K, et al. Ectopic pancreas formation
in Hes1 -knockout mice reveals plasticity of endodermal progenitors of
the gut, bile duct, and pancreas. J Clin Invest 2006;116:1484–1493
124. Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. Sox9
coordinates a transcriptional network in pancreatic progenitor cells. Proc
Natl Acad Sci USA 2007;104:10500–10505
125. Henseleit KD, Nelson SB, Kuhlbrodt K, Hennings JC, Ericson J, Sander M.
NKX6 transcription factor activity is required for alpha- and beta-cell
development in the pancreas. Development 2005;132:3139–3149
126. Nelson SB, Schaffer AE, Sander M. The transcription factors Nkx6.1 and
Nkx6.2 possess equivalent activities in promoting beta-cell fate speci-
ﬁcation in Pdx11 pancreatic progenitor cells. Development 2007;134:
2491–2500
CURRENT PERSPECTIVES IN b-CELL DEVELOPMENT
376 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.org